Our focused analysis of TCGA ovarian cancer data did not identify mutations in SMAD4; however, we did identify significant dysregulation of key TGF-β/SMAD genes, despite the fact that the vast majority of samples are from primary tumors. This evidence concerns the gene TGFB1 and ovarian carcinoma.